Coronavirus pandemic delay Mylan and Pfizer’s generics mergerMylan’s merger with Pfizer’s off-patent drug business has been delayed until later this year because of the coronavirus Share XCoronavirus pandemic delay Mylan and Pfizer’s generics mergerhttps://pharmaphorum.com/news/coronavirus-pandemic-delay-mylan-and-pfizers-generics-merger/
AbbVie/Allergan merger cleared in EU with brazikumab sell-offAbbVie and Allergan’s $63 billion merger has been cleared by European regulators, who have approved the sell-off of Share XAbbVie/Allergan merger cleared in EU with brazikumab sell-offhttps://pharmaphorum.com/news/abbvie-allergan-merger-cleared-in-eu-with-brazikumab-sell-off/
Gilead to buy immuno-oncology firm Forty Seven for $4.9bnGilead is to buy immuno-oncology firm Forty Seven for $4.9 billion, adding an antibody targeting several blood cancers Share XGilead to buy immuno-oncology firm Forty Seven for $4.9bnhttps://pharmaphorum.com/news/gilead-to-buy-immuno-oncology-firm-forty-seven-for-4-9bn/
Takeda buys US biotech PvP Biologics for $330 millionTakeda has bought US biotech PvP Biologics for $330 million, adding a potential new form of therapy for Share XTakeda buys US biotech PvP Biologics for $330 millionhttps://pharmaphorum.com/news/takeda-buys-us-biotech-pvp-biologics-for-330-million/
Stada expands OTC business with portfolio of GSK drugsGermany’s Stada is to expand its over-the-counter business after agreeing to buy a portfolio of consumer health products Share XStada expands OTC business with portfolio of GSK drugshttps://pharmaphorum.com/news/stada-expands-otc-business-with-portfolio-of-gsk-drugs/
How cell and gene therapies are transforming pharma deal-makingAfter decades of clinical research targeting development of more “personalised” medicines, the biotechnology sector is now starting to Share XHow cell and gene therapies are transforming pharma deal-makinghttps://pharmaphorum.com/r-d/views-analysis-r-d/how-cell-and-gene-therapies-are-transforming-pharma-deal-making/
Lilly targets quarterly deals worth up to $5bn to boost R&DEli Lilly is targeting a deal worth between $1 billion to $5 billion every quarter in 2020 as Share XLilly targets quarterly deals worth up to $5bn to boost R&Dhttps://pharmaphorum.com/news/lilly-targets-quarterly-deals-worth-up-to-5bn-boost-rd/
Almirall strikes option deal to buy Bioniz and dermatology drug BNZ-1Almirall has begun an option agreement with California’s Bioniz, which could see it buy the entire company and Share XAlmirall strikes option deal to buy Bioniz and dermatology drug BNZ-1https://pharmaphorum.com/news/almirall-strikes-option-deal-to-buy-bioniz-and-dermatology-drug-bnz-1/
DNA sequencers Illumina and PacBio call off $1.2bn mergerCalifornia-based DNA sequencing firms Illumina and Pacific Biosciences have called off their proposed $1.2 billion merger, after deciding Share XDNA sequencers Illumina and PacBio call off $1.2bn mergerhttps://pharmaphorum.com/news/dna-sequencers-illumina-and-pacific-call-off-1-2-bn-merger/
